Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ferring to Take Over Gonax’s Japan Authorization from Astellas
January 13, 2023
- Xofluza Adds Pediatric Indication in Europe: Roche
January 13, 2023
- Alfresa Sets Up Regenerative Medicine Unit to Supply Master Cells, Eyes Distribution
January 12, 2023
- Kaken, Axcelead Hook Up on New Drug Discovery
January 12, 2023
- Mitsubishi Tanabe to End Sales of Lexapro as Deal Expires
January 12, 2023
- Takatsugu Den Tapped as Biogen Japan’s New President
January 12, 2023
- Opdivo Extends Best-Selling Streak to 12 Months: Encise
January 12, 2023
- Eisai Files Alzheimer’s Med Lecanemab in Europe
January 12, 2023
- Kaken Snags Japan Rights to CymaBay Med for Primary Biliary Cholangitis
January 11, 2023
- Otsuka, Schrodinger in Neurology Drug Discovery Collaboration
January 11, 2023
- US FDA Accepts Rexulti sNDA for Alzheimer’s Agitation: Otsuka/Lundbeck
January 11, 2023
- Astellas to Test Selecta’s IgG Protease with Pompe Gene Therapy
January 11, 2023
- NeuroDerm’s Parkinson’s Med Hits Main Goal in PIII
January 11, 2023
- AnGes, miRaX Ink Option Pact for MicroRNA Research
January 11, 2023
- Forxiga Now Available for Heart Failure Regardless of LVEF
January 11, 2023
- AbbVie, Eisai to End Humira Copromotion in June
January 11, 2023
- Japan Ethical Drug Sales Up 2.1% in November: Crecon
January 11, 2023
- Official Margin Proposal Only Realistic for Partial Introduction: Crecon President
January 10, 2023
- Top-Tier Pharma Companies, Mid-Sized Peers Mixed on Special PMP Step: New Year Confab
January 10, 2023
- Leqembi Likely to Hit Peak Sales after 2030, US$26,500 Price Matches Value: Eisai CEO
January 10, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…